Next Article in Journal
Tryptophan Attenuates the Effects of OTA on Intestinal Morphology and Local IgA/IgY Production in Broiler Chicks
Previous Article in Journal
Efficacy of Potentially Probiotic Fruit-Derived Lactobacillus fermentum, L. paracasei and L. plantarum to Remove Aflatoxin M1 In Vitro
Open AccessArticle

Treatment of Localized and Referred Masticatory Myofascial Pain with Botulinum Toxin Injection

1
Department of Oral and Maxillofacial Surgery, Virgen del Rocio University Hospital, 41013 Seville, Spain
2
Department of Surgery, School of Medicine, University of Seville, 41009 Seville, Spain
*
Author to whom correspondence should be addressed.
Received: 29 October 2020 / Revised: 2 December 2020 / Accepted: 20 December 2020 / Published: 23 December 2020
(This article belongs to the Section Bacterial Toxins)
Botulinum toxin type A (BTA) injection is considered an available alternative treatment for myofascial pain. However, its efficacy in treating masticatory myofascial pain syndrome (MMPS) remains unclear. The purpose of this study was to evaluate whether the BTA injection into the affected muscles would significantly reduce pain and improve function, and to assess its efficacy, safety, and therapeutic indications in a randomized, single-center clinical trial. Sixty patients with MMPS were randomized into three groups evenly to receive a single session injection of saline solution (SS group), lidocaine (LD group), and BTA (BTA group) in the masseter, temporal, and pterygoid muscles after an electromyographic study. Patients’ pain was classified as localized or referred according to the DC/TMD classification. Assessments were performed on pre-treatment, and subsequently, on days 7, 14, 28, 60, 90, and 180. A significant reduction in pain and improvement of mandibular movements was found in the BTA group compared to the SS and LD groups. The response lasted until day 180 and was more intense in patients with localized myalgia and focused myofascial pain than in referred remote pain. No significant adverse reactions were observed. A single BTA injection can be considered an effective treatment option in patients with localized MMPS by reducing pain and improving mandibular movements, which persisted up to 6 months. View Full-Text
Keywords: temporomandibular disorders; masticatory myofascial pain syndrome; botulinum toxin; randomized controlled trial temporomandibular disorders; masticatory myofascial pain syndrome; botulinum toxin; randomized controlled trial
Show Figures

Figure 1

MDPI and ACS Style

Montes-Carmona, J.-F.; Gonzalez-Perez, L.-M.; Infante-Cossio, P. Treatment of Localized and Referred Masticatory Myofascial Pain with Botulinum Toxin Injection. Toxins 2021, 13, 6. https://doi.org/10.3390/toxins13010006

AMA Style

Montes-Carmona J-F, Gonzalez-Perez L-M, Infante-Cossio P. Treatment of Localized and Referred Masticatory Myofascial Pain with Botulinum Toxin Injection. Toxins. 2021; 13(1):6. https://doi.org/10.3390/toxins13010006

Chicago/Turabian Style

Montes-Carmona, Jose-Francisco; Gonzalez-Perez, Luis-Miguel; Infante-Cossio, Pedro. 2021. "Treatment of Localized and Referred Masticatory Myofascial Pain with Botulinum Toxin Injection" Toxins 13, no. 1: 6. https://doi.org/10.3390/toxins13010006

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop